Furthermore, we speculated whether this combination could be expanded to AML without FLT3‐ITD, so we tested the combination regimen in AML cell lines and AML patients without FLT3‐ITD, which resulted in varying degrees of synergistic effects (Fig. 6C–F; Fig. S2A–C). The gene discussed is FLT3; the disease is acute myeloid leukemia.